Sun Pharmaceutical Industries Limited (SUNPHARMA:NSE) Annual Income Statement (INR)
SUNPHARMA:NSE Quarterly Financials (INR)
Frequently Asked Questions About Sun Pharmaceutical Industries Limited (SUNPHARMA:NSE) Stock
Sun Pharmaceutical Industries Limited's (SUNPHARMA:NSE) last reported annual revenue was INR 432.79 Billion.
Sun Pharmaceutical Industries Limited's (SUNPHARMA:NSE) annual revenue growth rate based on the revenue reported in the past 5 years is : 10.67%
Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) is profitable as of its last reported annual financials.
The net profit margin for Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) from its laster reported year is 19.58%
The return on equity (ROE) for Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) from its last reported annual financials is : 14.31%
The return on assets (ROA) for Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) from its last reported annual financials is : 7.98%
The return on invested capital (ROIC) for Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) from its last reported annual financials is : 15.14%
The Debt to Equity ratio for Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) from its last reported annual financials is : 1.00%
The dividend yield for Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) from its laster reported year is 0.78%
Sun Pharmaceutical Industries Limited's(SUNPHARMA:NSE) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SUNPHARMA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
